Cardiovascular Disease

Xemilofiban Summary (continued page 3 of 3)

1. REFERENCES

1. Cox D, Dooley M, Theroux P, Crean P, Fitzgerald D. Fibrinogen receptor kinetics and platelet function in patients treated with the oral GP IIb/IIIa antagonist orbofiban. Thromb Haemost 1999; 82 (suppl):727 Abstract.

2. Ault KA, Cannon CP, Mitchell J, et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. J Am Coll Cardiol 1999; 33:634-639.

3. Jennings LK, White MM, Mendoza MC, Cholera S, Slack SM. Comparison of pharmacodynamic effects of GP IIb/IIIa receptor blockade. Circulation 1998; 98:359 Abstract.

4. Peter K, Schwartz M, Ylänne J, Moser M, et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Blood 1998; 92: 3240-3249.

5. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001;103:2572-2578.

6. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888-1894.

7. Kabbani SS, Aggarwai A, Terrien EF, et al. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol. 2002;89:647-650.

8. Lakkis N, Lakiss N, Bobek J, and Farmer J. Platelet Inhibition With Tirofiban Early During Percutaneous Coronary Intervention: Dosing Revisited Cathet Cardiovasc Intervent 2002;56:474-477.

9. The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet. 2001;357:1905-14.

10. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. Lancet. 2000;355:337-345.

11. Chew DP, Bhatt DL, Sapp S, et al. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation. 2001;103:201-206.

12. Quinn MJ, Plow EF, Topol, EJ. Platelet Glycoprotein IIb/IIIa Inhibitors Recognition of a Two-Edged Sword? Circulation. 2002;106:379-385.

13. O'Neill W, Serruys P, Knudtson M, van Es G-A, et al. Long-term treatment with platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. N Eng J Med 2000; 342:1316-1324.

14. Steinhubl S, Talley J, Kereiakes D, Baraden G, et al. Presence of angiographically visible thrombus, but not clinical syndrome, is associated with lower levels of platelet inhibition with a GPIIb/IIIa inhibitor in patients undergoing a percutaneous coronary intervention. Results from the GOLD study. ACC 2000 (Abstract).

15. Cox D, Dooley M, Theroux P, Crean P, Fitzgerald D. Fibrinogen receptor kinetics and platelet function in patients treated with the oral GP IIb/IIIa antagonist orbofiban. Thromb Haemost 1999; 82 (suppl):727 Abstract.

16. Ault KA, Cannon CP, Mitchell J, et al. Platelet activation in patients after an acute coronary syndrome:results from the TIMI-12 trial. J Am Coll Cardiol 1999; 33:634-639.

17. Jennings LK, White MM, Mendoza MC, Cholera S, Slack SM. Comparison of pharmacodynamic effects of GP IIb/IIIa receptor blockade. Circulation 1998; 98:359 Abstract.

18. Peter K, Schwarz M, Ylanne J, Kohler B, Moser M, Nordt T, et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Blood 1998; 92:3240-3249.

19. Topol E, Moliterno D, Herrmann H, Powers E, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344: 1888-1894.

20. Wilson M, Jamal H, Wischet P and Reid P. Comparison of the number of patients needed to treat with abciximab, Eptifibatide and Tirofiban to prevent death or myocardial infarction. Eur Heat J 2000; 12 (Abstr Suppl): 650.

page 3 of 3

Site created and maintained by Opposable Thumb Digital.